Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cardiovascular disease and aging are key contributors to myocardial remodeling, often leading to fibrosis, cellular hypertrophy, and impaired cardiac function. Understanding these structural changes is essential for explaining the pathophysiology of heart failure. This study examined histopathological changes in myocardial tissue from a post-mortem cadaver with heart failure. Two age-matched cadavers without cardiac disease were used as controls. Ventricular tissue samples were thin-sectioned and stained for collagen deposition and cellular morphology using Masson's Trichrome and Cresyl Violet dyes. Histopathological findings showed the presence of increased collagen deposition and fibrosis in the myocardial tissue with heart failure, consistent with a stiffened myocardium. Additionally, Cresyl Violet staining showed cardiomyocyte hypertrophy compared to control samples, suggesting cellular remodeling, which is well characterized following heart failure. These findings provide further histological evidence of myocardial remodeling in heart failure, characterized by fibrosis and cardiomyocyte hypertrophy. Further quantitative analysis is needed to deepen our understanding of these pathological changes and their implications for cardiac function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345069PMC
http://dx.doi.org/10.7759/cureus.87889DOI Listing

Publication Analysis

Top Keywords

heart failure
24
myocardial remodeling
12
remodeling heart
8
cardiac function
8
myocardial tissue
8
collagen deposition
8
cresyl violet
8
heart
6
failure
6
myocardial
5

Similar Publications

Importance: Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but treatable cause of heart failure (HF) in older individuals that occurs in the context of normal wild-type (ATTRwt-CA) or an abnormal inherited (ATTRv-CA) TTR gene variant. While the most common inherited TTR variant, V142I, occurs in 3% to 4% of self-identified Black Americans and is associated with excess morbidity and mortality, the prevalence of ATTR-CA in this at-risk population is unknown.

Objective: To define the prevalence of ATTR-CA and proportions attributable to ATTRwt-CA or ATTRv-CA among older Black and Caribbean Hispanic individuals with HF.

View Article and Find Full Text PDF

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.

View Article and Find Full Text PDF

From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.

Curr Atheroscler Rep

September 2025

Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.

Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.

Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.

View Article and Find Full Text PDF

Impact of diabetes on outcomes of patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease undergoing percutaneous coronary intervention.

Clin Res Cardiol

September 2025

Department of Cardiology, University Heart Center, University Hospital Zurich, Center for Translational and Experimental Cardiology (CTEC), University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.

Background: Diabetic patients with ST-segment elevation myocardial infarction (STEMI) are at an increased risk of cardiovascular events as compared to non-diabetic patients. This analysis investigated outcomes of diabetic patients presenting with multivessel disease (MVD) and STEMI in a contemporary trial and the relevance of an immediate versus staged multivessel PCI strategy in this high-risk population.

Methods: Patients enrolled in the MULTISTARS AMI trial were stratified according to the presence/absence of diabetes.

View Article and Find Full Text PDF

Small Interfering RNA Therapy Targeting the Long Noncoding RNA SMILR for Therapeutic Intervention in Coronary Artery Bypass Graft Failure.

JACC Basic Transl Sci

September 2025

BHF Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands. Electronic address: andy.bak

Coronary artery bypass graft (CABG) surgery remains the gold standard of care to prevent myocardial ischemia in patients with advanced atherosclerosis; however, poor long-term graft patency remains a considerable and long-standing problem. Excessive vascular smooth muscle cell (SMC) proliferation in the grafted tissue is recognized as central to late CABG failure. We previously identified SMILR, a human-specific SMC-enriched long noncoding RNA that drives SMC proliferation, suggesting that targeting SMILR expression could be a novel way to prevent neointima formation, and thus CABG failure.

View Article and Find Full Text PDF